Sotorasib is a targeted anti-cancer medication and a selective, irreversible KRAS G12C inhibitor indicated for the treatment of specific cancers, including non-small cell lung cancer, colorectal cancer,… Read more
![Chemical structure of 4-((R)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F4-R-4-Acryloyl-2-methylpiperazin-1-yl-6-fluoro-7-2-fluoro-6-hydroxyphenyl-1-2-isopropyl-4-methylpyridin-3-ylpyrido23-dpyrimidin-21H-one.png&w=3840&q=75)
![Chemical structure of 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2252403-56-6-4-S-4-Acryloyl-2-methylpiperazin-1-yl-6-fluoro-7-2-fluoro-6-hydroxyphenyl-1-2-isopropyl-4-methylpyridin-3-ylpyrido23-dpyrimidin-21H-one.png&w=3840&q=75)




Sotorasib is a targeted anti-cancer medication and a selective, irreversible KRAS G12C inhibitor indicated for the treatment of specific cancers, including non-small cell lung cancer, colorectal cancer, and appendiceal cancer harboring the KRAS G12C mutation. To support the rigorous demands of pharmaceutical quality control and regulatory compliance, this category provides high-quality reference standards for Sotorasib, including its active pharmaceutical ingredient, known process-related and degradation impurities, structural isomers, nitroso impurities, and metabolic derivatives. Laboratories rely on these materials, alongside stable isotope labelled compounds, to facilitate accurate impurity profiling, method validation, and quantitative analytical testing. By utilizing these precise reference materials, researchers and analytical chemists can ensure the consistency and safety of Sotorasib formulations throughout the drug development lifecycle and post-market surveillance.